Biomx Inc Cash Flow Conversion Efficiency
Biomx Inc cash flow conversion efficiency. Based on the latest financial reports, Biomx Inc (PHGE) has a cash flow conversion efficiency ratio of -0.685x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.18 Million) by net assets ($10.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biomx Inc (2017–2024)
Cash flow conversion efficiency of Biomx Inc from 2017 to 2024. This chart illustrates how Biomx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHGE stock price for real-time trading data and today's change.
Biomx Inc Cash Flow Conversion Ratio Explained
Biomx Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biomx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomx Inc ranked by their cash flow conversion efficiency. Also see market value of Biomx Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magnetite Mines Ltd
AU:MGT
|
-0.030x |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
0.029x |
|
EKF Diagnostics Holdings Plc
LSE:EKF
|
0.046x |
|
MT Educare Limited
NSE:MTEDUCARE
|
-0.429x |
|
MFC Industrial Real Estate Investment Trust
BK:MIT
|
-25.926x |
|
Baroyeca Gold & Silver Inc
V:BGS
|
0.194x |
|
Usha Martin Education & Solutions Limited
NSE:UMESLTD
|
0.019x |
|
Fsport AB
ST:FSPORT
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Biomx Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Biomx Inc from 2017 to 2024. Review financial agility of Biomx Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $24.15 Million | $-36.98 Million | -1.531x | +77.83% |
| 2023-12-31 | $3.08 Million | $-21.29 Million | -6.909x | -399.64% |
| 2022-12-31 | $21.04 Million | $-29.09 Million | -1.383x | -138.38% |
| 2021-12-31 | $47.53 Million | $-27.57 Million | -0.580x | -36.36% |
| 2020-12-31 | $57.47 Million | $-24.45 Million | -0.425x | -104.40% |
| 2019-12-31 | $84.46 Million | $-17.58 Million | -0.208x | +21.19% |
| 2018-12-31 | $42.80 Million | $-11.30 Million | -0.264x | +25.73% |
| 2017-12-31 | $11.53 Million | $-4.10 Million | -0.356x | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more